EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
复制标题
DOI：
10.1126/science.1099314
复制
发表时间：
2004-06-04
期刊：
影响因子：
56.9
通讯作者：
Meyerson, M
中科院分区：
文献类型：
--
作者：
Paez, JG;Jänne, PA;Meyerson, M
对非小细胞肺癌(NSCLC)及其配对的正常组织中的受体酪氨酸激酶基因进行了测序。来自日本的58个未经选择的肿瘤中有15个发现了表皮生长因子受体基因EGFR的体细胞突变，来自美国的61个肿瘤中有1个发现了体细胞突变。在一些非小细胞肺癌患者中，使用EGFR激酶抑制剂吉非替尼(易瑞沙)治疗可导致肿瘤消退，在日本更为常见。在对吉非替尼治疗有反应的美国患者的额外肺癌样本中发现了EGFR突变，在对吉非替尼抑制生长高度敏感的肺腺癌细胞株中发现了EGFR突变，但在对吉非替尼不敏感的肿瘤或细胞系中没有发现EGFR突变。这些结果表明，EGFR突变可能预示着对吉非替尼的敏感性。
Receptor tyrosine kinase genes were sequenced in non - small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U. S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.